Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats - PubMed (original) (raw)
. 2010 Oct;38(10):1779-84.
doi: 10.1124/dmd.110.033936. Epub 2010 Jul 15.
Affiliations
- PMID: 20634337
- DOI: 10.1124/dmd.110.033936
Extensive intestinal first-pass elimination and predominant hepatic distribution of berberine explain its low plasma levels in rats
Yi-Tong Liu et al. Drug Metab Dispos. 2010 Oct.
Abstract
Berberine, one of the most commonly used natural products, exhibits a poor plasma concentration-effect relationship whose underlying mechanisms remain largely unclear. This study was designed to test the hypothesis that extensive first-pass elimination and abundant tissue distribution of berberine may be its specific pharmacokinetic properties. For that, four different dosing routes, intragastric, intraduodenal, intraportal, and intravenous, were used to investigate the gastric, intestinal, and hepatic first-pass elimination of berberine. After intragastric dosing, approximately half of berberine ran intact through the gastrointestinal tract and another half was disposed of by the small intestine, leading to an extremely low extent of absolute oral bioavailability in rats (0.36%). Moreover, the major berberine metabolites were identified and quantified in rat enterocyte S9 fractions, portal vein plasma, and intestinal perfusates; plasma concentrations and tissue distribution of berberine and its major metabolites were determined as well. Data indicated that M1, M2 glucuronide, and M3 were the major metabolites generated from the small intestine and that there was a 70-fold increase in the ratio of the area under the concentration-time curve value for berberine (liver versus plasma). We conclude that intestinal first-pass elimination of berberine is the major barrier of its oral bioavailability and that its high extraction and distribution in the liver could be other important factors that lead to its low plasma levels in rats.
Similar articles
- Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK, Kim JW, Kim YH, Kim YG, Kim SG, Lee MG. Bae SK, et al. Biopharm Drug Dispos. 2005 May;26(4):129-34. doi: 10.1002/bdd.439. Biopharm Drug Dispos. 2005. PMID: 15744718 - Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
Kang HE, Cho YK, Jung HY, Choi KY, Sohn SI, Baek SR, Lee MG. Kang HE, et al. Xenobiotica. 2009 Jun;39(6):465-75. doi: 10.1080/00498250902890151. Xenobiotica. 2009. PMID: 19480552 - Research progress on berberine with a special focus on its oral bioavailability.
Liu CS, Zheng YR, Zhang YF, Long XY. Liu CS, et al. Fitoterapia. 2016 Mar;109:274-82. doi: 10.1016/j.fitote.2016.02.001. Epub 2016 Feb 2. Fitoterapia. 2016. PMID: 26851175 Review. - The metabolism of berberine and its contribution to the pharmacological effects.
Wang K, Feng X, Chai L, Cao S, Qiu F. Wang K, et al. Drug Metab Rev. 2017 May;49(2):139-157. doi: 10.1080/03602532.2017.1306544. Epub 2017 Apr 3. Drug Metab Rev. 2017. PMID: 28290706 Review.
Cited by
- Advances in the pharmacological mechanisms of berberine in the treatment of fibrosis.
Liu X, Liang Q, Wang Y, Xiong S, Yue R. Liu X, et al. Front Pharmacol. 2024 Sep 20;15:1455058. doi: 10.3389/fphar.2024.1455058. eCollection 2024. Front Pharmacol. 2024. PMID: 39372209 Free PMC article. Review. - Neuroprotective effect and preparation methods of berberine.
Sunhe YX, Zhang YH, Fu RJ, Xu DQ, Tang YP. Sunhe YX, et al. Front Pharmacol. 2024 Sep 6;15:1429050. doi: 10.3389/fphar.2024.1429050. eCollection 2024. Front Pharmacol. 2024. PMID: 39309003 Free PMC article. Review. - Development of Proniosome Gel Formulation for CHIKV Infection.
Altay Benetti A, Thwin MT, Suhaimi A, Liang RST, Ng LF, Lum FM, Benetti C. Altay Benetti A, et al. Pharmaceutics. 2024 Jul 26;16(8):994. doi: 10.3390/pharmaceutics16080994. Pharmaceutics. 2024. PMID: 39204339 Free PMC article. - Transforming Cancer Treatment with Nanotechnology: The Role of Berberine as a Star Natural Compound.
Sun L, Lan J, Li Z, Zeng R, Shen Y, Zhang T, Ding Y. Sun L, et al. Int J Nanomedicine. 2024 Aug 22;19:8621-8640. doi: 10.2147/IJN.S469350. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39188860 Free PMC article. Review. - Inhaled tea polyphenol-loaded nanoparticles coated with platelet membranes largely attenuate asthmatic inflammation.
Ouyang S, Lu P, Li J, Jin H, Wu W, Luo R, Wang B, Huang X, Lian X, Huang G. Ouyang S, et al. Respir Res. 2024 Aug 17;25(1):311. doi: 10.1186/s12931-024-02947-3. Respir Res. 2024. PMID: 39154188 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous